Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression  by Nikkheslat, Naghmeh et al.
Brain, Behavior, and Immunity 48 (2015) 8–18Contents lists available at ScienceDirect
Brain, Behavior, and Immunity
journal homepage: www.elsevier .com/locate /ybrbiInsufﬁcient glucocorticoid signaling and elevated inﬂammation
in coronary heart disease patients with comorbid depressionhttp://dx.doi.org/10.1016/j.bbi.2015.02.002
0889-1591/ 2015 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Department of Psychological Medicine, Institute of
Psychiatry, King’s College London, Room 2-055, The James Black Centre, 125
Coldharbour Lane, London SE5 9NU, UK. Tel.: +44 (0) 20 7848 0807.
E-mail address: carmine.pariante@kcl.ac.uk (C.M. Pariante).Naghmeh Nikkheslat a,b, Patricia A. Zunszain a, Mark A. Horowitz a, Izabela G. Barbosa a, Jennie A. Parker b,
Aye-Mu Myint e, Markus J. Schwarz e, Andre T. Tylee d, Livia A. Carvalho c, Carmine M. Pariante a,⇑
aDepartment of Psychological Medicine, Institute of Psychiatry, King’s College London, UK
bDepartment of Life Sciences, University of Roehampton, London, UK
cDepartment of Epidemiology and Public Health, University College London, UK
dHealth Service and Population Research Department, Institute of Psychiatry, King’s College London, UK
e Faculty of Medicine, Ludwig-Maximilian University, Munich, Germany
a r t i c l e i n f oArticle history:
Received 4 November 2014
Received in revised form 19 January 2015
Accepted 3 February 2015
Available online 12 February 2015
Keywords:
Major depressive disorders
Cardiovascular risk factors
Neuroendocrine
Stress
Cytokine
Corticosteroid receptor
Kynureninea b s t r a c t
Coronary heart disease (CHD) and depression are very common and often co-existing disorders. In addi-
tion to psychological and social morbidity, depression exacerbates adverse cardiac outcomes in CHD
patients. Inﬂammation has been proposed as one of the mechanisms involved in the association between
these two debilitating diseases. Therefore, the present study aimed to evaluate inﬂammatory responses
as well as to investigate the pathophysiological mechanisms underlying the putative inﬂammatory
activation in CHD patients with and without depression, by assessing the function of two important bio-
logical factors regulating inﬂammation, the hypothalamus–pituitary–adrenal (HPA) axis and the gluco-
corticoid receptor (GR). Eighty-three CHD patients with (n = 28) and without (n = 55) comorbid
depression were recruited from primary care services in South London. Depression status was assessed
by means of Clinical Interview Schedule Revised for diagnosis of depression, and Beck Depression
Inventory for the presence of depressive symptoms. Serum C-reactive protein (CRP), plasma vascular
endothelial growth factor (VEGF), and plasma and salivary cortisol were measured using commercially
available ELISA kits. Gene expression of GR and interleukin-6 (IL-6) were conducted via qPCR. GR sensitiv-
ity was evaluated in vitro in isolated peripheral blood mononuclear cells using the dexamethasone inhibi-
tion of lipopolysaccharide-stimulated IL-6 levels. Serum levels of kynurenine pathway metabolites were
measured using high performance liquid chromatography. Our results show that CHD patients with
depression had higher levels of CRP, IL-6 gene expression, and VEGF compared with CHD non-depressed,
as well as lower plasma and saliva cortisol levels. The CHD depressed group also exhibited a reduction in
GR expression and sensitivity. Finally, tryptophan levels were signiﬁcantly lower in patients with depres-
sion, who also showed an increased kynurenine/tryptophan ratio. In conclusion, CHD patients with
depression had elevated levels of inﬂammation in the context of HPA axis hypoactivity, GR resistance,
and increased activation of the kynurenine pathway. Reduced cortisol bioavailability and attenuated glu-
cocorticoid responsiveness due to decreased expression and sensitivity of GR may lead to insufﬁcient glu-
cocorticoid signaling and thus elevation of inﬂammation in these patients.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heart disease and depression are twovery commonand often co-
existing disorders affecting the populationworldwide. According to
the World Health Organization Global Burden of Disease Survey,
coronary heart disease (CHD) and major depressive disorder(MDD) are currently the ﬁrst and second causes of disability in
developed countries, and it is estimated that this will apply to all
countries throughout the world by the year 2020 (Blazer, 2000;
Licinio et al., 2002). The prevalence of depression among patients
with establishedCHD is considerablyhigher as compared to thegen-
eral population (Carney and Freedland, 2003). Depression exacer-
bates adverse cardiac outcomes in CHD patients, besides
worsening the psychological and social morbidity. Indeed, depres-
sion has been recognized as a negative prognostic indicator and an
independent factor greatly increasing the risk of cardiovascular
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known cardiac risk factors (Jiang et al., 2002; Meijer et al., 2011;
Miller et al., 2002).
The mechanisms associated with the link between the two dis-
eases are not completely understood and identifying the patho-
physiological mechanisms underlying the increased incidence of
depression in patients with CHD remains a big challenge (Whooley
and Wong, 2013). Inﬂammation has been recognized as a common
link between these two mental and physical disorders (Halaris,
2013; Kop and Gottdiener, 2005; Maes et al., 2011; McCaffery
et al., 2006). Indeed, failure of regulatory responses in the control
of inﬂammation could be particularly important in the development
of depression in CHD patients, when the immune system fails to
induce an appropriate anti-inﬂammatory response to inhibit exces-
sive release of pro-inﬂammatory cytokines (Davidson, 2012).
Inﬂammation plays a central role in pathogenesis of CHD and is
involved in all stages of atherosclerosis including initiation, prop-
agation, and activation of atherosclerotic plaque, ultimately lead-
ing to thrombogenesis. Indeed, CHD patients show higher
circulating pro-inﬂammatory cytokines, higher clinical markers of
inﬂammation like C-reactive protein (CRP), and association with
higher expression of inﬂammatory genes (Hansson, 2005; Libby,
2006). Downregulation of the anti-inﬂammatory cytokine IL-10
and upregulation of the pro-inﬂammatory cytokines IL-6 and
TNF-a have been reported in chronic heart failure patients with
depressive symptoms (Parissis et al., 2004), and patients with
myocardial infarction have increased plasma IL-6 and CRP concen-
trations and altered response to the anti-inﬂammatory properties
of glucocorticoids, which independently correlate with depressive
symptoms (Pizzi et al., 2008). Activated inﬂammatory responses
are obvious candidate for the increased comorbidity with depres-
sion. Increased inﬂammation has been suggested to induce depres-
sive symptoms not only by directly affecting the brain but also
modulating the serotonergic system (Dantzer et al., 2011;
Wichers and Maes, 2004) through indoleamine-2,3-dioxygenase
(IDO) enzyme overstimulation, possibly leading to tryptophan
(TRP) depletion (Wichers and Maes, 2002). In fact, in response to
inﬂammatory challenges, TRP metabolism shifts towards the for-
mation of kynurenine (KYN) metabolites (Lapin and Oxenkrug,
1969) with an increased production of 3-hydroxykynurenine (3-
HK) and the depressogenic, quinolinic acid (NMDA receptor ago-
nist, neurotoxic metabolite) rather than kynurenic acid (KYNA)
(N-methyl d-aspartate (NMDA) receptor antagonist, neuroprotec-
tive metabolite) (Myint and Kim, 2003).
Hypothalamus–pituitary–adrenal (HPA) axis also plays a
fundamental role as a regulatory system in stress responses and
inﬂammation. Alteration of the HPA axis is observed in a signiﬁ-
cant proportion of patients with major depression and seems to
reﬂect an impaired ability of cortisol to exert its physiological
effects including the negative feedback on the HPA axis itself as
well as the anti-inﬂammatory effects at the peripheral level
(Pariante, 2006; Pariante and Miller, 2001). Indeed, excessive
inﬂammation due to impaired glucocorticoid receptor (GR)
sensitivity has been found in patients with MDD (Pace et al.,
2007; Stewart et al., 2009), in elderly individuals (Rohleder et al.,
2002), and in at-risk patients for cardiovascular disease (Carvalho
et al., 2015). It has been also postulated that glucocorticoid resis-
tance itself may occur as a result of chronic stress and prolonged
exposure to inﬂammatory cytokines (Miller et al., 1999).
The present study focuses on the potential mechanisms under-
lying the pathophysiology of depression in heart disease patients,
to further advance our current understanding of the link between
these two debilitating conditions by investigating the possible bio-
logical pathways involved through assessing inﬂammatory
response, HPA axis activity, GR sensitivity and kynurenine path-
way, all in the same population.2. Materials and methods
2.1. Subjects
The study subjects were recruited from participants of the
UPBEAT UK research programme led by Prof. Andre Tylee
(Institute of Psychiatry, Kings College London) examining patients
with CHD and evaluating psychosocial predictors of depression in
CHD. In the UPBEAT cohort study (Tylee et al., 2011), patients were
recruited from sixteen practices across South London. Patients
were eligible if they were registered on the primary care CHD reg-
isters which were kept by general practices under the Quality and
Outcomes Framework. Patients were on the GP CHD registers
because of documented history of myocardial infarction (MI)
(around 50%) up to 20 years previously or had had angina or an
intervention at some time (angioplasty, stent, bypass surgery
etc.). Depression was assessed through baseline interview for psy-
chiatric evaluation of mental state using the Clinical Interview
Schedule-Revised (CIS-R) (Lewis et al., 1992) based on ICD-10 code
(International Classiﬁcation of Diseases-10) (Walters et al., 2014).
CHD patients who had given prior authorization to be contacted
for related-studies were invited to participate in the present bio-
logical project. The priori exclusion criteria included patients tak-
ing corticosteroid medications such as prednisolone, patients
with other relevant medical co-morbidity including asthma, can-
cer, and arthritis, as well as those suffering from acute infections.
Furthermore, based on the CIS-R assessment patients with a pri-
mary diagnosis of other psychiatric conditions (panic, obsessive–
compulsive disorder, phobias, generalized anxiety disorder, and
mixed depression anxiety disorder) were also excluded. The
depression status was deﬁned based on the CIS-R assessment
(Lewis et al., 1992) for a diagnosis of depression as well as the con-
current presence of depressive symptoms, using the Beck depres-
sion inventory (BDI) score (Beck et al., 1961) obtained at the
time of the biological sample collection. The cut-off BDI scores
P10 was used to indicate the presence of depressive symptoms
(Beck et al., 1988). Therefore, CHD patients who were both CIS-R
and BDI positive were categorized as CHD depressed (CHD-D),
and CHD patients who were both CIS-R and BDI negative were cat-
egorized as CHD non depressed (CHD). This project was approved
by the National Research Ethics Service, East Kent Local Research
Ethics committee (reference number 09/H1103/19); The
Institution Review Boards at the Institute of Psychiatry, King’s
College London (reference numbers 07/H0809/38 and 322/2003);
and the University of Roehampton Ethics Committee (reference
number BHS 10/025). Patients were interviewed, and asked to
complete the BDI followed by collecting peripheral venous blood.
Non-fasting blood samples were collected between 8:30 am and
10:30 am. Written informed consent was obtained from all partici-
pants. A total of n = 28 CHD-D patients and n = 55 CHD patients
were included in the study. The demographic information for the
participants is presented in Table 1. The effect of age, gender,
employment statues were analyzed in all subsequent analysis.
Some CHD-D patients were taking selective serotonin reuptake
inhibitor or tricyclic antidepressants, and again their effects were
analyzed.2.2. Salivary cortisol
Saliva samples were collected from participants according to
our previously published procedure (Mondelli et al., 2010).
Participants were asked to complete the BDI questionnaire on the
day of sampling. Individuals who described problems during sam-
ple collection in the self-recorded questionnaire provided, or who
did not respect the time-intervals required, were taken out of the
Table 1
Characteristics of the coronary heart disease subjects with and without depression.
CHD (n = 55) CHD-D (n = 28) Test and signiﬁcance
Sociodemographic
Age (years) (mean) 70 ± 1 69 ± 2 t (81) = 0.72, p = 0.48
Gender, male (%) 89 54 v2 = 13.26, p = 0.001⁄⁄
Ethnicity (% of white) 91 82 v2 = 1.35, p = 0.25
Marital status [n (%)]
Married/divorced/widowed/single 75/9/7/9 59/11/15/15 v2 = 2.28, p = 0.52
Educational level [n (%)]
610 years/>11 years 43/57 59/41 v2 = 2.00, p = 0.16
Employment status [n (%)]
Employed/retired/unemployed 16/80/4 11/70/19 v2 = 5.26, p = 0.07
Smoking status [n (%)]
Current/Ex/Never 33/53/14 32/47/21 v2 = 0.67, p = 0.72
Psychometric
CIS-R (%) 0 100
BDI score (mean ± SEM)
At the time of blood collection 4.2 ± 0.4 19.0 ± 1.3
At the time of saliva collection 4.3 ± 0.4 18.2 ± 1.7
History of depression (%) 0 54
Family history of depression (%) 13 36
Cardiac factors and diagnoses
Myocardial infarction (%) 47 36 v2 = 1.01, p = 0.32
Heart rate (mean ± SEM) 58.1 ± 1.5 67.0 ± 4.0 t (52) = 2.09, p = 0.047⁄
Hypertension (%) 69 79 v2 = 0.92, p = 0.34
BMI (kg/m2) (mean ± SEM) 29.2 ± 0.8 30.2 ± 1.5 U = 733.0, z = 0.23, p = 0.82
High cholesterol (%) 66 56 v2 = 0.84, p = 0.36
Family history of heart problems (%) 65 70 v2 = 0.25, p = 0.62
Diabetic CHD (%) 18 29 v2 = 1.18, p = 0.28
Concomitant medications
Antidepressants (%) 0 39
Statin (%) 89 80 v2 = 0.99, p = 0.32
ASA (%) 71 80 v2 = 0.69, p = 0.41
Anticoagulants (%) 21 20 v2 = 0.01, p = 0.91
Antihypertensive (%) 94 92 v2 = 0.14, p = 0.71
Beta-blockers (%) 60 52 v2 = 0.40, p = 0.53
ACE-inhibitors (%) 67 52 v2 = 1.69, p = 0.19
Ca2+-channel inhibitors (%) 25 20 v2 = 0.24, p = 0.63
BMI = body mass index, ACE = angiotensin-converting-enzyme inhibitor, ASA = acetylsalicylic acid.
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cially available high sensitivity salivary cortisol enzyme
immunoassay kit (Salimetrics). SoftMax Pro 4.8 software was used
to calculate the cortisol values, following a 4-parameter ﬁt. The
analytical sensitivity was set to 0.33 nmol/l. Inter and intra-assay
co-efﬁcient of variations ranged 8–11% and 6–10%, respectively.
To investigate the responsiveness of the HPA axis, the repeated
measures of salivary cortisol was used to calculate the area under
the curve (AUC) of the cortisol awakening response (CAR) and diur-
nal cortisol with respect to the increase (AUCI) as well as with
respect to the ground (AUCG). The formulas for the calculations
of the AUC were derived from the trapezoidal formula introduced
by Pruessner et al. (2003).2.3. Peripheral cortisol and CRP measurements
Blood samples collected in sodium-heparin and clot activator
containing tubes were centrifuged to separate plasma and serum,
respectively. The samples were stored at 80 C until assayed.
The samples were analyzed at the biochemistry laboratory,
KingsPath, at King’s College Hospital. The levels of peripheral CRP
were determined performing the Cormay high sensitivity CRP
(HsCRP) assay (P.Z. Cormay, Lublin, Poland). The minimum detect-
able concentration of hsCRP was 0.01 mg/dL. Inter and intra-assay
co-efﬁcient of variations were <10%. Cortisol reagents weresupplied by Siemens Healthcare Diagnostics Ltd., Camberley,
Surrey, UK. The minimum detectable concentration was 30 nmol/
L. Inter and intra-assay co-efﬁcient of variations were <10%.2.4. Gene expression analysis
Blood samples for gene expression analysis of IL-6 and GR
mRNA were collected using PAXgene Tubes (Qiagen). Isolation of
RNA was performed using the PAXgene Blood RNA Kit (Qiagen)
according to manufacturer´s instructions. The RNA quality and
quantity were assessed by evaluation of the A260/280 and A260/
230 ratios using a Nanodrop spectrometer (NanoDrop
Technologies, USA). Samples were kept frozen at 80 C until fur-
ther use. One microgram of total RNA was used for cDNA synthesis
and for subsequent gene expression analysis in quantitative Real
Time PCR (qPCR) performed using HOT FIREPol EvaGreen qPCR
(Solis BioDyne, Tartu, Estonia) according to the SYBR Green
method. For each target primer set a validation experiment was
performed to demonstrate that PCR efﬁciencies were within the
range of 90–100% and approximately equal to the efﬁciencies of
the reference genes; glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), beta-actin (ACTB), and beta-2-microglobulin (B2M).
Each sample was assayed in duplicate and each target gene was
normalized to the geometric mean of the expression of the three
housekeeping genes as reference. Pfafﬂ equation was used to
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2001). This method has been previously used in our group
(Anacker et al., 2011; Cattaneo et al., 2013).
2.5. Vascular endothelial growth factor (VEGF) measurement in
plasma
The quantitative determination of vascular endothelial growth
factor (VEGF) concentrations in plasma samples were measured by
a commercially available ELISA kit (R&D systems, Minneapolis,
MN, USA) (Rosti et al., 2007). Microplate reader (Beckman Coulter
DTX 880)was used to determine optical density at 450 nmwith cor-
rection at 570 nm. SoftMax Pro 4.8 software was used to calculate
the VEGF values. Inter- and intra-assay variations were <10%.
2.6. GR function evaluation in vitro
Sodium-heparinized blood was diluted 1:1 with phosphate buf-
fered saline (PBS). Peripheral blood mononuclear cells (PBMC)
were isolated by Ficoll-Paque density gradient centrifugation, as
per previous publications (Knijff et al., 2007; Sarkar et al., 2003).
The procedure was carried out by layering diluted blood on top
of Ficoll (2:1 e.g. 30 ml diluted blood on 15 ml of Ficoll) in a
50 ml polypropylene tube. The tube was centrifuged at 1000 g for
15 min at room temperature, and PBMC were re-suspended in
PBS to the total volume of 50 ml, and centrifuged at 800 g for
10 min at room temperature. The supernatant was discarded and
PBMC rich pellet was re-suspended in a cryovial in 1 ml cold cell
culture ﬂuid 1 (CF1) medium consisted of 10% FCS (fetal calf
serum), and 1% PEN-STREP (Penicillin–Streptomycin), and 90%
RPMI 1640 with 25 mM Hepes and Ultraglutamin-1 medium.
Freshly prepared cell culture ﬂuid 2 (CF2) containing 80% CF1
and 20% DMSO were then added 1:1 slowly in droplets to the cell
suspension. The cells were distributed in 1 ml aliquots in precooled
cryovials ready for storage using slow temperature-lowering
method by incubating them in an isopropyl alcohol bath in Cryo
1 C freezing container (Mr. Frosty polyethylene vial holder). The
cryovials in the freezing container were placed at 80 C overnight
and then transferred into liquid nitrogen for long-term storage
until future use. GR sensitivity was analyzed directly on isolated
and stored PBMC using the ‘‘dexamethasone inhibition of
lipopolysaccharide (LPS)-stimulated IL-6 levels’’ technique accord-
ing to a previously published method with slight modiﬁcations
(Carvalho et al., 2008, 2010). Recovery and viability of PBMC were
examined by trypan blue exclusion technique, and cryopreserved
and thawed cells contained greater than 95% viable recovered cells.
PBMC were cultured in a 96-well round-bottomed tissue culture
plate (Falcon, 3077) at a concentration of 50  104 cells/ml
(100 K/well) in CF1. Cells were cultured without stimulation
(Unst), or stimulated by LPS (Sigma) (1 ng/ml). Next, dexametha-
sone (DEX) (Sigma) was used at different concentrations (106,
107, 3  108, 108, 109 M) to inhibit the production of IL-6
mediated by the GR. Each condition was assayed in duplicate.
PBMC were then incubated for 24 h at 37 C, under 5% CO2 and
humidiﬁed air. After 24 h, the plate was centrifuged at 1000 g for
10 min at 4 C. The supernatants from each well were harvested
and stored at 20 C until they were assayed the following day
for measurements of IL-6 levels via ELISA as per previously pub-
lished work with slight modiﬁcations (Knijff et al., 2007). A 96-well
ELISA plate (Costar 3590) was coated overnight at 4 C adding
100 ll diluted (1:1000) IL-6 speciﬁc capture antibody
(Invitrogen: Ms mAb Anti-Hu IL-6) to each well. After overnight
incubation, the wells were then emptied and tapped on a paper ﬁl-
ter. Next, 300 ll block buffer, PBS containing 0.5% BSA (bovine
serum albumin, Sigma) solution, was added to each well, and the
plate was incubated for 2 h in room temperature. After blockingstep, the plate was washed 4 times using the plate washer machine
and freshly prepared wash buffer (MilliQ water containing 0.9%
Nacl and 0.05% Tween20 solution). The supernatant samples were
diluted to a measurable solution (1:2, 1:100, and 1:50 for Unst, LPS,
and DEX, respectively) in working buffer (PBS containing 0.5%
BSA). The standard solutions of IL-6 (R&D: recombinant human
IL-6) were prepared in serial dilution (500, 250, 125, 62.5, 31.25,
15.63, 7.8, 3.9, 1.95, 0 ng/ml) for the standard curve. 100 ll of
diluted samples and standard solutions were aliquoted in duplicate
in the appropriate wells. 50 ll diluted (1:500) IL-6 detection anti-
body (Invitrogen: Ms mAb Anti-Hu IL-6 Biotin) were thereafter
added to each well followed by incubation for 2 h on a plate shaker
at room temperature. After another washing step, 100 ll diluted
(1:15,000) streptavidin poly HRP (Thermo scientiﬁc) was added
to enhance the reaction, and the plate was incubated for 30 min
under continuous shaking at room temperature. The plate was
then washed 5 times. The reaction was developed in dark after
adding 100 ll of TMB substrate (Thermo Scientiﬁc), and then
stopped by adding 100 ll 1 M H2SO4 when the color of Blank
and the standard solution in the lowest concentration started to
turn slightly blue (approximately after 3–5 min). The absorbance
at 450/620 nm was measured using ELISA reader (MULTISKANEX,
Thermo Electron Corporation). The concentrations of IL-6 in sam-
ples of supernatants were determined using GraphPad Prism
Software version 4.0 for windows, Inc., San Diego, California,
USA. Inter- and intra-assay variations were <10%. The analytical
sensitivity was set to 2 ng/mL. The values obtained from the levels
of IL-6 of the unstimulated cells were deducted from the LPS-
stimulated IL-6 levels for each condition. Glucocorticoid suppres-
sion was calculated by normalizing the data to LPS-stimulated IL-
6 levels (in the absence of dexamethasone), which was expressed
as 100% (Carvalho et al., 2010).
2.7. Tryptophan and kynurenine pathway analysis
Serum samples were sent to Dr. Aye Mu Myint and her col-
leagues in Germany (Laboratory for Psychoneuroimmunology,
Ludwig-Maximilians University, Munich) to determine the levels
of TRP, KYN, KYNA, and 3-HAA metabolites, using high perfor-
mance liquid chromatography (HPLC) method of Herve et al.
(1996) with some modiﬁcations as well as the recently published
method by Oades et al. (2010) to measure 3-HK. The following is
a brief description of the method used: KYN was detected spec-
trophotometrically at 365 nm. KYNA was detected ﬂuorimetrically
at an excitation wavelength of 334 nm and an emission wave-
length of 388 nm. KYNA was analyzed in plasma that was depro-
teinised using perchloric acid. 3-HK was measured at a
wavelength of 365 nm by UV detection. All of the analyses were
conducted using HPLC with a reversed phase C-18 column. The
3-HK analysis method has been validated showing an absolute
recovery of 85.8%, intra-day precision of 3.9%, and inter-day preci-
sion of 7.5%. A time series demonstrated total stability of the ana-
lyte 3-HK during the extraction and analysis steps for up to 3
repeated freezing/thawing cycles, which ensured the validity of
the analysis in samples that had already been thawed and frozen
again. The intra- and inter-assay coefﬁcients of variation ranged
from 5% to 7% for all of the metabolites. The kynurenine to trypto-
phan (KYN/TRP) ratio was calculated.
2.8. Data analysis
All statistical analyses were performed using SPSS software ver-
sion 20.0 and GraphPad Prism 4.0 for Windows. The data were
reported as the mean ± SEM. All data were tested for suitability
for parametric or non-parametric analysis. For comparing the bio-
logical factors assessed in this study between the two groups of
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sion, independent t-test or Mann–Whitney U-test was used, as
appropriate. Dichotomous variables were compared using Chi-
squared test. Correlations were assessed using Pearson’s product
moment correlation or Spearman’s correlation coefﬁcient where
the data violated parametric assumptions. For comparison of more
than two groups, One-way ANOVA analysis or Kruskal–Wallis test
were performed, as appropriate. General linear model (GLM) was
performed for taking into account the effect of covariates
(ANCOVA) such as gender, age, employment status, and antide-
pressant use on the ﬁndings. The p-values of <0.05 were considered
as signiﬁcant.3. Results
3.1. CHD patients with depression show higher levels of inﬂammation
Both CHD groups, with and without depression, exhibited mean
CRP levels greater than 3 mg/L, considered as being in high-riskTable 2
Inﬂammatory biomarkers measured in CHD patients with and without depression.
Inﬂammatory
biomarkers
CHD
(mean ± SEM)
CHD-D
(mean ± SEM)
Comparison analysis
Serum CRP (mg/L) 3.34 ± 0.75
n = 33
5.20 ± 0.99
n = 21
U = 224.50, Z = 2.17,
p = 0.030⁄
IL-6 gene
expression
1.14 ± 0.13
n = 23
3.22 ± 0.63
n = 16
U = 79.50, Z = 2.98,
p = 0.003⁄⁄
Plasma VEGF (pg/
mL)
94.28 ± 16.22
n = 29
173.13 ± 36.46
n = 21
U = 193.00, Z = 2.19,
p = 0.028⁄
CRP = C-reactive protein, IL-6 = interleukin-6, VEGF = vascular endothelial growth
factor.
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mean ± SEM. ⁄p < 0.05, ⁄⁄p < 0.01.group for cardiovascular events according to the American Heart
Association (see Table 2). However, mean inﬂammation was found
to be even higher (5.2 mg/L) in CHD patients with depression
(p < 0.05). CRP levels were found to be positively correlated with
heart rate in CHD patients (rs = 0.37, p = 0.008, n = 50). In order to
evaluate further the inﬂammatory response, we analyzed gene
expression levels of IL-6 mRNA; its expression was signiﬁcantly
increased in CHD depressed patients as compared with non-de-
pressed (2.8-fold increase, p < 0.01, Table 2). There were no dif-
ferences in the number of monocytes between the two groups:
(mean ± SEM); CHD 0.51 ± 0.03  10^9/L, CHD-D
0.48 ± 0.03  10^9/L, t (50) = 0.64, p = 0.5). Gender and age were
found to have a signiﬁcant effect on IL-6 expression;
F(1,36) = 4.226, p = 0.047 and F(1,36) = 6.167, p = 0.018, respec-
tively. However, the result held true after controlling for the effect
of these covariates (F(3,35) = 4.54, p = 0.04). We also analyzed
VEGF as another inﬂammatory marker, since its release is stimu-
lated by IL-6 and inhibited by glucocorticoids. Comparing the
two groups, CHD depressed patients showed signiﬁcantly higher
(almost twofold) plasma VEGF levels than CHD non-depressed
individuals (p < 0.05, Table 2).3.2. CHD patients with depression show lower cortisol in both plasma
and saliva
As demonstrated in Fig. 1a, CHD patients with depression had
lower (20%) plasma cortisol than non-depressed group
(p = 0.026). In addition, the depressed group exhibited signiﬁcantly
decreased cortisol levels in the ﬁrst hour after awakening com-
pared to CHD non-depressed (Two-way ANOVA, F(1,3) = 19.45,
n = 51, p < 0.0001), and post hoc tests indicated signiﬁcant ﬁndings
at 30 min and 60 min (Fig. 1b). The results from calculating the
area under the curve for the cortisol awakening response in respectCHD-D
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cortisol output during the ﬁrst hour post awakening: CAR AUCG,
(U = 176.0, p = 0.016). Calculating the area under the curve taking
into account the measurements of the ﬁrst hour post awakening
in respect to the increase from the baseline measurement (awa-
kening) showed a trend towards a decreased cortisol response in
CHD depressed compared to non-depressed group: CAR AUCI
(U = 205.0, p = 0.0796). Although, diurnal cortisol levels showed
lower cortisol values at each time point (awakening, 2 pm, and
bedtime) in CHD patients with depression compared with CHD
without depression (Fig. 1c), no statistically signiﬁcant difference
was found on the diurnal cortisol and the result only reached
trend-level in the Two-way ANOVA (F(1,2) = 3.39, p = 0.068).
There was no difference in awakening time between the two
groups: (mean ± SEM); CHD 7:04 ± 0:09 am, CHD-D 7:03 ± 0:22
am, t (51) = 0.013, p = 0.990).3.3. CHD patients with depression show decreased GR expression and
sensitivity
CHD depressed individuals exhibited signiﬁcantly reduced
expression of GR mRNA when compared with CHD non-depressed
(28%, p < 0.05). As expected, following in vitro stimulation ofPBMC by LPS, IL-6 levels were remarkably increased in both CHD
depressed and non-depressed patients (Fig. 2a). There was no dif-
ference between LPS-induced IL-6 levels between depressed and
non-depressed patients (mean ± SEM); CHD 10,050 ± 3415 ng/mL,
CHD-D 4195 ± 1142 ng/mL, t (25) = 1.38, p = 0.18. In vitro
dexamethasone inhibition of LPS-stimulated IL-6 production in
PBMC was measured as percentage suppression, to eliminate any
potential effects of this baseline difference in stimulated IL-6
levels. As illustrated in Fig. 2b, both CHD patients with and without
depression showed suppression of LPS-stimulated IL-6 levels in a
concentration-dependent manner. However, across all concentra-
tions of DEX, CHD depressed individuals exhibited higher levels
of IL-6 (two-way ANOVA, F(1,5) = 11.19, n = 27, p = 0.001), with
post hoc analyses showing signiﬁcant differences for 1 nM
(t = 2.91, p < 0.05).3.4. Activation of the kynurenine pathway in CHD patients with
depression
We investigated the tryptophan metabolism pathway by mea-
suring the circulatory levels of several metabolites. As presented
in Table 3, CHD depressed patients showed lower serum levels of
tryptophan when compared with CHD non-depressed individuals
Table 3
Serum levels of kynurenine pathway metabolites in CHD patients with and without depression.
CHD (n = 29) (mean ± SEM) CHD-D (n = 15) (mean ± SEM) Comparison analysis
TRP (lg/ml) 12.64 ± 0.64 10.42 ± 0.58 t (42) = 2.25, p = 0.03⁄
KYN (ng/ml) 843.50 ± 54.37 746.53 ± 42.29 U = 187.0, Z = 0.76, p = 0.45
KYN/TRP 62.21 ± 2.88 74.43 ± 5.26 t (42) = 2.22, p = 0.03⁄
KYNA (ng/ml) 15.57 ± 1.18 12.02 ± 1.43 t (42) = 1.83, p = 0.07
3-HK (ng/ml) 18.85 ± 1.78 18.40 ± 1.49 U = 192.5, Z = 0.62, p = 0.54
3-HAA (ng/ml) 34.31 ± 3.35 33.72 ± 5.48 U = 202.0, Z = 0.38, p = 0.70
TRP = tryptophan, KYN = Kynurenine, KYNA = Kynurenic acid, 3-HK = 3-hydroxykynurenin, 3-HAA = 3-hydroxyanthranilic acid.
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indicator of activated IDO, was signiﬁcantly higher in depressed
CHD compared with non-depressed patients (p = 0.03). Although
not statistically signiﬁcant, the depressed group showed a trend
towards less production of kynurenic acid (p = 0.07). The levels of
3-HK and 3-HAA did not differ between the two groups
(p > 0.05). CRP levels were associated with KYN/TRP ratio
(rs = 0.35, p = 0.028, n = 40).3.5. Covariate analyses
We analyzed the effects of a priori selected confounders (age,
gender, employment status, and antidepressants use) on serum
CRP, plasma VEGF, gene expression of IL-6 and GR, plasma cortisol,
cortisol awakening response, diurnal salivary cortisol, and cir-
culatory tryptophan and kynurenine levels. We found no effects
of any of these potential confounders (all p > 0.05).4. Discussion
The present results show that, in CHD patients, depression is
accompanied by elevated levels of inﬂammation in the context of
low cortisol output, GR resistance, and increased activation of the
kynurenine pathway. Although CHD patients without depression
already exhibit an activation of the inﬂammatory system as mea-
sured by circulatory levels of CRP, inﬂammation is even higher in
the presence of depression comorbidity. Consistent with high
CRP, CHD depressed individuals also display increased IL-6 gene
expression and plasma VEGF. While the association between CHD
and depression in relation to inﬂammation has been reported
before, the present study extends the ﬁndings by showing that
the depressed group exhibit insufﬁcient glucocorticoid signaling
due to both decreased hormone bioavailability as well as attenu-
ated glucocorticoid responsiveness. Indeed, CHD patients with
depression exhibit lower levels of cortisol as shown by a single
measurement in plasma and repeated measures in saliva. In addi-
tion, CHD patients with depression have signiﬁcantly lower
expression levels of GR mRNA and less functional ability of the
GR to respond to glucocorticoids. Our study also conﬁrms that ele-
vated inﬂammation is associated with effects on tryptophan meta-
bolism through activation of the kynurenine pathway, as revealed
by lower levels of tryptophan together with higher KYN/TRP ratio.
Again, higher CRP is associated with increased activity of IDO
enzyme. Therefore, the results suggest that an activated inﬂamma-
tory response may lead to increased rates of tryptophan
degradation.
CRP is known as a mediator and marker of atherosclerosis and
has been consistently reported to be a potent predictor of future
vascular serious events including myocardial infarction, ischemic
stroke, and sudden cardiac death. This predictive value has been
shown to be stronger than LDL cholesterol and also independent
of sex, age, blood pressure, cholesterol, smoking, and diabetes
(Ridker, 2003, 2007). On the other hand, elevation of inﬂammationand increased CRP concentration has been implicated in patho-
genesis of depression. Indeed, patients with major depression exhi-
bit evidence of activated inﬂammatory responses and elevated
levels of inﬂammatory cytokines such as TNF-a, IL-6 and CRP
(Empana et al., 2005). The phenomenon is linked to the alteration
of the central nervous system and contributes to depressive symp-
toms (Irwin and Miller, 2007). Recently, attention has been also
paid to disruption of the blood–brain-barrier (BBB) as another
potential mechanism underlying the pathogenesis of depression
in relation to inﬂammation. The hypothesis suggests breakdown
of BBB leads to the penetration of inﬂammatory molecules into
the brain (Shalev et al., 2009). CRP has been shown to be associated
with increased BBB permeability (Hsuchou et al., 2012), and there-
fore the (relatively) high CRP levels (average >3 mg/L) even in the
CHD patients without depression may indicate not only an
increased cardiovascular risk but also an increased risk of develop-
ing depression in the future. Furthermore, the even higher CRP
levels (average >5 mg/L) in the CHD depressed group is a signiﬁ-
cant cause of concern, since even a small elevation in CRP levels
greatly increases the risk of heart attack, angina, and more severe
cardiovascular complications. Indeed, we ﬁnd that heart rate,
which is increased in the depressed group, is also positively corre-
lated with CRP. Increased heart rate in depressed patients with
CHD has been described before (Carney et al., 1988, 1993), and it
has been shown to be an independent prognostic risk factor for
morbidity and mortality related to CHD (Dyer et al., 1980).
Moreover, the correlation between heart rate and CRP would sup-
port the notion of a bidirectional inﬂuence between inﬂammation
and cardiac function, but the cross-sectional nature of the data lim-
its the possibility of speculating on the direction of the causation.
Moreover, IL-6 (also higher in CHD depressed patients) is
believed to be a contributing factor in the stimulation of the pro-
cesses leading to the formation and propagation of coronary pla-
que, including release of adhesion molecules from endothelium
and platelet aggregation (Barton, 1996). Indeed, expression and
plasma concentration of IL-6 and its by product CRP have been
reported to be indicator of the intensity of inﬂammatory induced
coronary plaque and are associated with instability of the plaque
and vulnerability to rupture (Ikeda et al., 2001). Overexpression
of IL-6 is also shown to be associated with aging, possibly account-
ing for the development of chronic inﬂammatory conditions and
other physical complications, such as muscle atrophy, arthritis,
and osteoporosis (Ferrucci et al., 1999; Ershler and Keller, 2000).
In addition, elevation in the levels of IL-6 and CRP has been shown
to be associated with a remarkably increased mortality in older
people (Harris et al., 1999). These ﬁndings are important con-
sidering the age of the present participants, who are therefore at
increased risk of disability, cardiovascular events, and mortality.
Finally, higher VEGF in CHD patients with depression may also
contribute to worsening their cardiovascular condition. Originally
identiﬁed for its ability to promote vascular permeability (Senger
et al., 1986), VEGF is the most potent growth factor for endothelial
cells and a main regulator of angiogenesis and vasculogenesis
(Byrne et al., 2005; Keck et al., 1989) and has been shown to be
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2002), with some data suggesting an association between prog-
nosis of coronary atherosclerosis and elevated VEGF (Fleisch
et al., 1999). Taken together, our ﬁndings indicate that CHD
patients with comorbid depression are truly at high risk of future
cardiovascular events due to the widespread increase in potent
inﬂammatory biomarkers. The role of VEGF expands beyond the
vasculature, speciﬁcally in the brain. Known as a neurotrophic fac-
tor, VEGF is thought to exert neuroprotection (Storkebaum et al.,
2004) and increase neurogenesis (Jin et al., 2002) in addition to
vasculogenesis. The direct neurotrophic activity of VEGF in the
brain has shown to be exerted through stimulating axonal out-
growth and enhancing cell survival (Sondell et al., 1999), protect-
ing hippocampal neurons against glutamate mediated toxicity
(Matsuzaki et al., 2001), and inﬂuencing synaptic plasticity (Licht
et al., 2011) and transmission (McCloskey et al., 2005). Due to
the crucial involvement in the vascular system as well as
neurological processes, and considering the relationship between
CHD and depression, VEGF has been suggested to be one of the
molecular links underlying the comorbidity of these two disorders
(Warner-Schmidt and Duman, 2008). However, there are con-
siderable discrepancies among studies investigating VEGF in
depression. While some studies have reported increased VEGF
mRNA (Berent et al., 2014; Iga et al., 2007), serum (Berent et al.,
2014; Kahl et al., 2009) or plasma (Lee and Kim, 2012;
Takebayashi et al., 2010) levels in patients with MDD, others have
found signiﬁcant decreases in VEGF peripheral levels in depression
(Dome et al., 2009; Isung et al., 2012; Katsuura et al., 2011) or no
difference between patients with MDD and healthy controls
(Kotan et al., 2012; Ventriglia et al., 2009). A recent review assess-
ing clinical studies on VEGF and depression speculated that eleva-
tion in VEGF levels in patients with MDD appears to be due to the
response to the perceived stress associated with depression result-
ing in an attempted neuroprotective effect, whereas decreased
levels of VEGF seem to be observed in treatment-resistant
depressed patients whose brains are less able to undergo neuroge-
nesis processes (Clark-Raymond and Halaris, 2013).
In our study, compared to CHD non-depressed, CHD patients
with depression, show lower levels of cortisol both in plasma
and saliva, together with more blunted response to the stress of
awakening. Chronic inﬂammatory exposure in CHD is one of the
stressful challenges that these patients face, and adaptation to such
condition require involvement of neural–endocrine–immune
mechanisms (Chrousos and Gold, 1992; McEwen, 1998). The
impact of exposure to chronic or extreme stress on the neurobiol-
ogy of the HPA axis is well documented. Indeed, prolonged activa-
tion of the HPA axis has an adverse effect on health outcomes both
physically and emotionally (Sapolsky et al., 2000). Despite the
popularity of studies showing higher levels of cortisol in MDD as
a result of hyperactivity of the HPA axis and presence of GR resis-
tance (Carvalho et al., 2008; Pariante and Miller, 2001), not all the
studies have found the same results. While some studies reported
depressed patients show increased level of cortisol in cere-
brospinal ﬂuid, plasma and urine, consistent with overactivity of
the HPA axis; and enlargement of pituitary and adrenal glands
(Otte et al., 2004; Pariante and Miller, 2001; Stewart et al., 2009),
others explored the opposite ﬁndings. Indeed, decreased morning
cortisol in both serum and saliva samples have been reported in
depressed as well as vulnerable individuals in the community
(Strickland et al., 2002). There are also studies suggesting hypoac-
tivity of the HPA axis and hypocortisolism associated with late-life
depression (Morrison et al., 2000; Oldehinkel et al., 2001) and in
patients with physical comorbidity such as diabetes (Carvalho
et al., 2015). In fact, late-life depressive symptoms have been sug-
gested to be associated with both hyper and hypoactivity of the
HPA axis (Penninx et al., 2007), with studies suggesting thatphysical frailty and exhaustion are the underlying mechanisms
associated with HPA axis insufﬁciency among elderly with depres-
sion (Fries et al., 2005; Morrison et al., 2001; Oldehinkel et al.,
2001). Moreover, some studies have shown an association of hypo-
cortisolemia with physical complains and chronic fatigue after long
term HPA axis overstimulation under chronic physical stress (Fries
et al., 2005; Hellhammer et al., 2004). Decreased levels of cortisol
have been consistently shown in other stress-related conditions
including atypical depression (Gold and Chrousos, 2002), PTSD
(Yehuda, 2001), chronic fatigue syndrome and ﬁbromyalgia
(Crofford et al., 1994; Demitrack and Crofford, 1998). Some incon-
sistent ﬁndings have also been reported in regards to the associa-
tion of cortisol with depression in patients with cardiovascular
diseases. In the Heart and Soul Study, Otte and colleagues have
found an association between depression and elevated urinary cor-
tisol in CHD patients. However, increased cortisol has not been
found to be related to the worsening of cardiac function in these
patients (Otte et al., 2004). In another study in CHD patients,
depression was associated with ﬂatter diurnal cortisol rhythms,
which in turn contributed to prognosis of coronary atherosclerosis
(Bhattacharyya et al., 2008). However, lack of association between
depressive symptoms and diurnal cortisol proﬁle has been also
reported in patients following hospitalization with an acute coro-
nary syndrome (Molloy et al., 2008).
Based on our results, CHD individuals with depression also
show lower levels of GR mRNA expression, indicating less GR avail-
able for responding to the glucocorticoids, as well as impaired GR
sensitivity in PBMC. Although the etiology of GR resistance is
unknown, pro-inﬂammatory cytokines may generate glucocorti-
coid resistance by directly affecting functional capacity of GR at
multiple levels. Studies suggest that prolonged inﬂammation has
a direct effect in reducing GR sensitivity through the interaction
of cytokine signaling pathway with GR signaling pathway (Pace
et al., 2007). In addition, elevated inﬂammatory responses and
pro-inﬂammatory cytokines are known to increase expression of
GRb, which is a relatively inert isoform, affecting the active isoform
GRa involved in regulation of gene expression. GRb has been sug-
gested to decrease GR function by attenuating GRa transcriptional
activity (Webster et al., 2001; Wichers and Maes, 2002). Moreover,
cytokines may trigger glucocorticoid resistance by reducing GR
ligand and DNA binding capacities, inhibiting GR translocation to
the nucleus and inﬂuencing GR protein–protein interactions as
seen for example by activating the mitogen-activated protein
kinase (MAPK) signaling pathway in cytoplasm which leads to
phosphorylation of the receptor protein, thus diminishing GR tran-
scriptional activity (Pace et al., 2007; Raison and Miller, 2003). GR
resistance, as a result of chronic stress, can in turn further con-
tribute to a dysregulation of inﬂammation (Cohen et al., 2012).
This coexistence of GR resistance and increased inﬂammation at
a molecular level is consistent with a study on chronic stress in
humans, where caregivers to cancer patients were found to have
decreased expression of GR-dependent transcripts together with
increased expression of inﬂammatory genes and biomarkers
(Miller et al., 2008). Therefore, it appears that endogenous cortisol
secretion is insufﬁcient to limit inﬂammation in CHD patients with
depression, due to hypoactivity of the HPA axis and GR resistance,
leading to higher inﬂammatory response in these patients, which
in turn further maintains GR resistance. However, it is also impor-
tant to highlight one study that found increased, rather than
decreased, GR function in CHD patients, although a number of
methodological differences between may explain this discrepancy:
ﬁrst, patients were within 3 month after a myocardial infarction
(or a revascularization procedure), while our patients had chronic
conditions, likely resulting in increased inﬂammation occurring
over many years; second, the sample was slightly younger, aged
on average 60 years compared with our average age of 70; and
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rather than isolated PBMCs (Miller et al., 2005).
Finally, we found activation of the kynurenine pathway and
increased IDO activity in CHD patients with depression, leading
to lower peripheral levels of tryptophan (which in turn can puta-
tively lead to reduced serotonin synthesis in the brain). Indeed, evi-
dence suggests that alterations in inﬂammatory response in
relation to activation of the kynurenine pathway leading to the
imbalance between neuroprotective and neurotoxic metabolites
have been implicated in pathology of the psychiatric conditions,
including MDD (Myint et al., 2007, 2012; Myint and Kim, 2003).
On the other hand, previous studies on cardiovascular diseases
have also shown decreased tryptophan levels and higher KYN/
TRP ratio coincided with increased neopterin concentration (a mar-
ker of monocyte/macrophage activation) in CHD patients com-
pared to healthy controls (Wirleitner et al., 2003). In line with
our ﬁndings, a recently published study revealed an association
between KYN/TRP ratio and CRP as well as neopterin in CHD
patients, suggesting IDO activity to be related with immune activa-
tion (OZKAN et al., 2014). IDO activity is believed to be associated
with risk factors for atherosclerosis and prognosis of cardio-
vascular disorders (Niinisalo et al., 2008; Pedersen et al., 2011;
Pertovaara et al., 2007), and one study also showed an association
between depressive symptoms and carotid atherosclerosis that
involved IDO activation (Elovainio et al., 2011). Therefore, it
appears that elevated inﬂammation in our CHD depressed patients
not only can lead to further disruption in serotonergic system but
also worsening the cardiac outcome in this population.
One of the limitations of this study is the small sample size of
the group with depression. In addition, in some experiments, only
subgroups of patients were analyzed due to missing/insufﬁcient
biological samples. Furthermore, some potentially confounding
variables, such as left ventricular function, congestive heart failure,
or physical activity, have not been measured in this study. Finally,
it should be noted that the study participants were elderly, and the
clinical overlapping between older age and CHD makes it difﬁcult
to dissect the biological interaction between age, CHD and depres-
sion, also considering the age-related risk factors contributing to
depression, such as medical illnesses, frailty, functional decline,
and general disability (Bruce, 2002; Yoshimura et al., 2013).
Indeed, our ﬁndings may not necessarily extend to other pop-
ulations of younger depressed patients, since late-life depression
differs in terms of psychopathology as compared to depression in
younger adults; for example, depression in late life is more com-
mon as compared to midlife, with a more chronic course, and these
patients often only display some symptoms of depression, not
always meeting the strict criteria of the Diagnostic and Statistical
Manual of Mental Disorders for clinical depression (Beekman
et al., 2002; Kohn and Epstein-Lubow, 2006).
This study was cross-sectional; prospective investigations
would enable examining the longitudinal association between
heart disease and depression in relation to inﬂammation, and
whether high inﬂammation in non-depressed CHD patients makes
them more at risk of future depression. Indeed, identiﬁcation of
biomarkers, which predict future development of depression, will
have important translational signiﬁcance leading to identiﬁcation
of subjects that may beneﬁt from targeted therapeutic prophylactic
intervention.5. Conclusion
We propose that chronic inﬂammation in patients with CHD
contributes to the development of depression, which in turn leads
to further activation of inﬂammatory processes as reﬂected in joint
elevation in IL-6 expression and CRP as well as VEGF levels, whichis inadequately restrained by endogenous glucocorticoids that are
both lower and less able to act on the GR, and which lead to further
brain and metabolic dysfunction by activating the kynurenine
pathway. These ﬁndings may provide a better understanding of
the role of inﬂammation in the pathogenesis of depression in coro-
nary heart disease and an ample support of the observations in
regards to inﬂammation as a remarkable link between these two
devastating disorders.
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